Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Margarida Magalhaes-Silverman
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01849783CT.gov Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00536601CT.gov High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Systemic Amyloidosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Melphalan (this asset) | Margarida Magalhaes-Silverman | P2 | B · 57 |
| Adriamycin | Margarida Magalhaes-Silverman | P2 | B |
| Dexasone | Margarida Magalhaes-Silverman | P2 | B |
| Bortezomib | Margarida Magalhaes-Silverman | P2 | B |
| Cyclophosphamide | Margarida Magalhaes-Silverman | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Margarida Magalhaes-Silverman | P2 | B |
| Etoposide | Margarida Magalhaes-Silverman | P2 | B |
| Evuzamitide | University of Tennessee Graduate School of Medicine | P1/2 | B |
| Thalidomide | Margarida Magalhaes-Silverman | P2 | B |
+16 more in the Primary Systemic Amyloidosis cohort
Other indications for Melphalan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P4 | BBB · 76 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2/3 | BBB · 76 |
| Cancer Of Unknown Primary Site | — | P2/3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Melphalan in Primary Systemic Amyloidosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/melphalan-primary-systemic-amyloidosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →